An observational study in PANS and Pediatric Acute-Onset Neuropsychiatric Syndrome, sponsored by University of Cagliari. Recruiting at 5 sites in Italy. Open to participants aged 3 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by University of Cagliari · Observational
Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) is a complex neuropsychiatric disorder characterized by the abrupt onset of symptoms and currently diagnosed mainly on clinical criteria, as reliable diagnostic biomarkers are still lacking. The primary objective of this project is to identify and validate a panel of neurophysiological, molecular, genetic, and metabolomic biomarkers associated with disease onset, clinical trajectory, and response to antimicrobial, anti-inflammatory, and immunomodulatory treatments. Identifying objective biomarkers will improve diagnostic accuracy, facilitate earlier diagnosis, clarify disease mechanisms, and support the development of more targeted therapeutic strategies.
PANS is currently considered a multifactorial immune-mediated inflammatory brain disorder resulting from the interaction of genetic susceptibility, immune dysregulation, infections, and environmental factors such as stress or trauma. Current evidence suggests that both innate and adaptive immune responses contribute to disease pathophysiology through interactions between the peripheral immune system and the central nervous system.
The pathogenic process may begin during fetal life through Maternal Immune Activation (MIA), whereby maternal infections or immune dysregulation induce inflammatory responses that increase susceptibility to neurodevelopmental disorders. During the postnatal period, infectious agents, including viruses, Mycoplasma pneumoniae, and Haemophilus influenzae, may trigger immune activation, leading to blood-brain barrier disruption, glial activation, and abnormalities within cortico-basal ganglia circuits thought to underlie PANS symptoms.
To achieve these objectives, the project will adopt a multidisciplinary translational approach that combines the enrolment and characterization of pediatric patients with PANS with complementary studies in animal models. Particular emphasis will be placed on clinical and sleep features, together with molecular and metabolomic profiling, to identify biomarkers with diagnostic and prognostic value and to investigate the biological pathways underlying disease onset and progression.
Given the high clinical, social, and economic burden of PANS, which frequently follows a chronic or relapsing-remitting course requiring long-term healthcare support, earlier diagnosis and a better understanding of disease mechanisms could significantly improve patient management. More broadly, the project will contribute to understanding the immune-mediated pathogenic pathways underlying PANS and related neurodevelopmental disorders, supporting the transition from symptom-based classification toward mechanism-based diagnosis and treatment.
The specific aim 1 is the Neurophysiological and clinical characterization of sleep and Electroencephalographic (EEG) patterns. This aim focuses on the systematic characterization of sleep architecture and EEG features in pediatric patients with Pediatric Acute Neuropsychiatric Syndrome (PANS), a domain that remains largely unexplored despite growing clinical evidence of sleep disturbances in this population. Preliminary reports and consensus guidelines suggest the presence of nonspecific EEG abnormalities, including focal or generalized slowing and, less frequently, epileptiform activity. However, no structured, systematic evaluation has been conducted to define their prevalence, clinical correlates, and longitudinal evolution.
Polysomnographic studies in PANS suggest a high burden of sleep disturbances, including insomnia, parasomnias, periodic limb movement disorder, and Rapid Eye Movement stage (REM) sleep abnormalities such as REM sleep without atonia and REM behavior disorder. These alterations may contribute to daytime cognitive dysfunction, attentional deficits, fatigue, and "brain fog," which are commonly reported in affected children. All enrolled patients will undergo standardized overnight polysomnography and EEG recording at baseline and after treatment. Sleep architecture, respiratory parameters, limb movements, and EEG activity will be analyzed according to American Academy of Sleep Medicine (AASM) criteria. The aim is to define objective neurophysiological markers associated with disease severity and clinical symptom clusters.
A cohort of at least 50 pediatric patients (3-18 years) with a clinical diagnosis of PANS will be recruited at the Child and Adolescent Neuropsychiatry Unit of the Azienda Ospedaliero Universitaria (AOU) Policlinico "G. Martino" in Messina. Diagnosis will be confirmed independently by two child neuropsychiatrists according to established consensus criteria. Clinical characterization will include standardized assessments of symptom severity and functioning, including psychometric scales, and cognitive evaluation using age-appropriate intellectual evaluation through the Wechsler scales. A detailed clinical history will be collected, including the disease course, infectious triggers, autoimmune comorbidities, family history, and treatment response.
A control group of at least 30 age- and sex-matched neurotypical subjects will be enrolled. Exclusion criteria include major medical, neurological, or psychiatric conditions and current immunomodulatory treatments.
All participants will undergo comprehensive laboratory screening to exclude systemic conditions and will be evaluated using standardized cognitive and neuropsychological batteries. Sleep assessment will include a clinical interview, overnight polysomnography, and a standard EEG recording, all performed within the same week as the clinical evaluation. Sleep scoring will follow AASM criteria and will be conducted by experienced sleep medicine specialists. Data from clinical, neuropsychological, neurophysiological, genetic, and molecular assessments will be integrated into a unified database for multilevel correlation analyses.
The specific Aim 2 regards the identification of molecular, genetic, and metabolomic biomarkers. This aim is designed to identify biological markers associated with PANS onset, clinical heterogeneity, and treatment response using a multi-omics approach that integrates genetic, transcriptomic, and metabolic data. Genetic susceptibility will be investigated using whole-exome sequencing (WES) in parent-proband trios, with a focus on de novo and ultra-rare variants affecting immune regulation, microglial function, and synaptic pathways that have been implicated in neurodevelopmental disorders. Circulating microRNAs (miRNAs) will be profiled by Ribonucleic Acid (RNA) sequencing of whole-blood samples to identify dysregulated miRNA signatures that may reflect central nervous system immune and synaptic alterations. Selected findings will be validated by Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR), and bioinformatic analyses will be used to define affected molecular pathways. Metabolomic profiling will be performed using Proton Nuclear Magnetic Resonance (¹H-NMR) spectroscopy to characterize serum metabolic signatures associated with PANS and to assess correlations with symptom severity. In addition, plasma levels of brain-derived neurotrophic factor (BDNF) and markers of oxidative stress and inflammation (e.g., IL-6 and kynurenine pathway metabolites) will be quantified to assess neuroimmune and neurotrophic dysregulation. Collectively, these approaches aim to identify convergent biomarker signatures reflecting underlying disease mechanisms and clinically relevant phenotypes. For reach this aim, Serum samples will be analyzed using 1H-NMR spectroscopy for untargeted metabolomic profiling. Multivariate statistical analyses will be applied to identify metabolic signatures differentiating PANS patients from controls and to explore correlations with clinical severity. Genetic analyses will be conducted using whole-exome sequencing in parent-proband trios to identify rare and de novo variants that may be involved in immune regulation and synaptic function. miRNA profiling will be performed on whole blood using next-generation sequencing platforms, followed by validation through RT-qPCR. Bioinformatic analyses will identify enriched pathways and predicted gene targets. Plasma and serum biomarkers, including BDNF, inflammatory cytokines, and oxidative stress markers, will be quantified using standardized biochemical assays.
Finally, specific Aim 3 is the translational investigation using a maternal immune activation (MIA) animal model to provide causal mechanisms underlying PANS-related phenotypes. A maternal immune activation (MIA) model will be used to mimic prenatal immune challenge and its impact on neurodevelopment. Pregnant Sprague-Dawley rats will receive poly(I:C) during gestation to induce a controlled maternal immune response. Offspring will be evaluated during postnatal development and adulthood using behavioral paradigms assessing stereotyped behavior, social interaction, and cognitive performance. Neurophysiological alterations will be assessed through in vivo electrophysiological recordings in the ventral tegmental area and prefrontal cortex, focusing on dopaminergic and cortical circuit activity. Fast-scan cyclic voltammetry will be used to evaluate dopamine dynamics in the nucleus accumbens. Complementary ex vivo patch-clamp and multi-electrode array recordings will further characterize neuronal excitability and network connectivity. Molecular analyses will include quantification of miRNA expression, gene expression profiles, and biochemical markers of neuroinflammation, oxidative stress, and neurotrophic signaling in brain tissue and blood. Cross-species comparisons will be performed to identify conserved molecular signatures between human PANS patients and the MIA model.
MIA will be induced in pregnant Sprague-Dawley rats using poly(I:C) administration during gestation. Offspring will be evaluated for behavioral, cognitive, and social phenotypes using standardized paradigms, including stereotypy assessment, three-chamber social interaction tests, and novel object recognition. Neurophysiological recordings will be performed in vivo and ex vivo to assess dopaminergic and cortical circuit function. Dopamine dynamics will be measured in the nucleus accumbens using fast-scan cyclic voltammetry.
Molecular analyses will include gene expression and miRNA profiling in brain regions and peripheral blood, alongside quantification of inflammatory, oxidative, and neurotrophic markers using enzyme-linked immunosorbent assay (ELISA), Western blot, high-performance liquid chromatography (HPLC), and RT-qPCR.
180 studies on the registry are indexed under Neuroinflammatory Diseases; 80 are open to participants now.
This study's planned enrollment of 80 is close to the median of 88 across 64 observational studies indexed under Neuroinflammatory Diseases.
Browse Neuroinflammatory Diseases studies →University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Compared within Neuroinflammatory Diseases, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
The study population consists of children and adolescents with a diagnosis of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) recruited at the referral center, together with age- and sex-matched neurotypical healthy controls recruited from the same geographical area.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (for the PANS group):
The control group must include children without diseases, neurodevelopmental or psychiatric disorders, and with adequate academic performance and functional level.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children and adolescents diagnosed with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) undergoing clinical, neurophysiological, genetic, metabolomic, miRNA and sleep assessments.
Diagnostic Test: Psycodiagnostic evaluation · Diagnostic Test: Polysomnography · Diagnostic Test: 1H-NMR analysis · Diagnostic Test: miRNA sequencing
Age- and sex-matched neurotypical children without autoimmune, neurodevelopmental or psychiatric disorders undergoing the same assessment protocol for comparison.
Diagnostic Test: Psycodiagnostic evaluation · Diagnostic Test: Polysomnography · Diagnostic Test: 1H-NMR analysis · Diagnostic Test: miRNA sequencing
Psycodiagnostic scales and tests to identify and quantify symptoms: Pediatric Acute Neuropsychiatric Symptom Scale (PANSS); Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS); punteggio Yale Global Tic Severity Scale (YGTSS); Pediatric Anxiety Rating Scale (PARS); Children's Global Assessment Scale (C-GAS). Il quoziente intellettivo (QI) sarà misurato mediante la WPPSI-III (Wechsler Preschool and Primary Scale of Intelligence- III) o la WISC-IV (Wechsler Intelligence Scale for Children - IV), according to children's age
will be performed by means of a video complete polysomnography (PSG), following the AASM standard criteria. The following parameters will be included in the PSG study: EEG, electrooculogram, electromyogram (EMG) of submental muscle, EMG of bilateral tibialis anterior muscle and one single-lead ECG. The sleep respiratory pattern will be assessed by means of nasal airflow, thoracic and abdominal respiratory effort, and oxygen saturation, during the study night. Sleep signals will be stored on hard disk in European data format for further analysis. The polysomnographic parameters to be evaluated are: Total Sleep Time (TST), Sleep Efficiency (SE), Sleep Latency (SL), REM Latency, N1% TST, N2% TST, N3% TST, REM% TST, Wake After Sleep Onset % (WASO%), Awakenings, Periodic Limb Movement Index (PLMI), RSWA (REM Sleep Without Atonia), RAI (REM atonia index), and the presence of frequent change position. Standard EEG will be performed following International 10-20 system
the samples will be analyzed with a Varian UNITY INOVA 500 spectrometer, which will operate at 499 MHz and equip with a 5 mm triple resonance probe with z-axis pulsed field gradients and an auto-sampler with 50 locations. One dimensional 1H-NMR spectra will be collected at 300 K with a pre-sat pulse sequence to suppress the residual water's signal. The spectra will be recorded with a spectral width of 6,000 Hz; a frequency of 2 Hz; an acquisition time of 1.5 s; a relaxation delay of 2 ms; and a 90 pulse of 9.5 ms. The number of scans will be at least of 250. Using MestReNova software, each 1H-NMR spectrum will be divided into consecutive "bins" of 0.04 ppm. A spectral area will be selected for the investigation, excluding the other regions in order to remove variations in the pre-saturation of the residual water resonance and spectral regions of noise. The study aims to isolate genomic DNA from PANS patients' peripheral blood leukocytes. Whole-exome sequencing (WES) analysis will be c
miRNA sequencing will be performed at the Center for Omics Sciences facility at IRCCS Ospedale San Raffaele. Bioinformatic analysis will be performed on the raw data obtained from sequencing. To detect differentially expressed miRNAs, a negative binomial regression considering several biological covariates will be used, and miRNAs with log2(FC)\>\|1 a p-value\<0.05 will be selected. Multiple testing correction will be applied to control the false-discovery rate using the Benjamini-Hochberg (BH) procedure. Blood level expression of selected miRNAs will be evaluated by qPCR. Plasma/Serum levels of selected markers will be evaluated by qPCR, western blot or ELISA analyses.
Concentrations of predefined inflammatory biomarkers
Inflammatory biomarker concentrations will be measured in biological samples using predefined laboratory assays. Associations between biomarker concentrations and psychiatric, neuropsychological, and polysomnographic measures will be evaluated using predefined statistical analyses.
Time frame: From the enrollment through study completion, an average of 36 months
Expression levels of selected microRNAs
Relative expression levels of predefined microRNAs measured in peripheral blood samples using RT-qPCR.
Time frame: From the biological samples collection to the end of analysis, an average of 2 years
Metabolomic profile
Concentrations of predefined metabolites measured in biological samples using \^1H-NMR spectroscopy and other planned metabolomic analyses.
Time frame: From the biological samples collection to the end of analysis, an average of 2 years
Frequency of pathogenic and likely pathogenic genetic variants
Number and type of predefined genetic variants identified by whole-exome sequencing.
Time frame: From the biological samples collection to the end of analysis, an average of 2 years
Molecular signatures in the maternal immune activation model
Comparison of predefined inflammatory, genetic, metabolomic, and microRNA profiles between patients with PANS and the maternal immune activation animal model.
Time frame: From the biological samples collection to the end of analysis, an average of 2 years
Diagnostic performance of candidate biomarkers
Diagnostic performance of predefined inflammatory, genetic, metabolomic, and microRNA biomarkers for distinguishing patients with PANS from controls, assessed using appropriate statistical measures (ROC, PCA).
Time frame: From enrollment through study completion (approximately 36 months)
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Cagliari